Aspergillosis-Pipeline Review, H1 2015

Aspergillosis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6708IDB
  • |
  • Pages: 98
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Aspergillosis-Pipeline Review, H1 2015


Global Markets Direct's, 'Aspergillosis-Pipeline Review, H1 2015', provides an overview of the Aspergillosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Aspergillosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aspergillosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Aspergillosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Aspergillosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Aspergillosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Aspergillosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Aspergillosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Aspergillosis Overview 9

Therapeutics Development 10

Pipeline Products for Aspergillosis-Overview 10

Pipeline Products for Aspergillosis-Comparative Analysis 11

Aspergillosis-Therapeutics under Development by Companies 12

Aspergillosis-Therapeutics under Investigation by Universities/Institutes 14

Aspergillosis-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Aspergillosis-Products under Development by Companies 18

Aspergillosis-Products under Investigation by Universities/Institutes 20

Aspergillosis-Companies Involved in Therapeutics Development 21

Amplyx Pharmaceuticals, Inc. 21

Astellas Pharma Inc. 22

Aureogen Biosciences, Inc. 23

Basilea Pharmaceutica AG 24

Biomar Microbial Technologies 25

Eisai Co., Ltd. 26

F2G Ltd 27

iCo Therapeutics Inc. 28

MABLife S.A.S 29

Merck & Co., Inc. 30

Nanomerics Ltd 31

Novabiotics Ltd 32

Pulmocide Ltd 33

Scynexis, Inc. 34

Sealife PHARMA GMBH 35

Sigma-Tau S.p.A. 36

Vical Incorporated 37

Aspergillosis-Therapeutics Assessment 38

Assessment by Monotherapy Products 38

Assessment by Target 39

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

amphotericin b-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

amphotericin B-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

amphotericin b NanoDisk-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ASP-2397-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

ASP-9726-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

AUGC-10-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

AUGC-15-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

C-001-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

C-016-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

E-1210-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

E-1211-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

F-901318-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

FK506 Analogues-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

GBV-042-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

isavuconazonium sulfate-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

KB-425796C-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

MAT-401-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

MDN-0018-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

NP-339-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

posaconazole-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

PTX-3-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

SCY-078-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

SLP-0901-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

SLP-0904-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Small Molecules for Aspergillosis and Candidiasis-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Small Molecules for Fungal Infections-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Small Molecules for Fungal Infections-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Small Molecules for Invasive Pulmonary Aspergillosis-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Small Molecules to Inhibit ABC Transporter for Fungal Infections-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Aspergillosis-Recent Pipeline Updates 79

Aspergillosis-Dormant Projects 87

Aspergillosis-Dormant Projects 87

Aspergillosis-Discontinued Products 88

Aspergillosis-Product Development Milestones 89

Featured News & Press Releases 89

Apr 27, 2015: Astellas Launches CRESEMBA (isavuconazonium sulfate) in the United States for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis 89

Apr 23, 2015: CRESEMBA (isavuconazonium sulfate) Data to be Presented at the European Congress of Clinical Microbiology and Infectious Diseases 89

Mar 25, 2015: Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas 90

Mar 06, 2015: FDA approves new antifungal drug Cresemba 91

Jan 22, 2015: Astellas Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval of CRESEMBA (isavuconazonium) for Treatment of Invasive Aspergillosis and Mucormycosis 92

Jan 09, 2015: SCYNEXIS Receives FDA Fast Track Designation for Oral Formulation of SCY-078 for the Treatment of Patients With Invasive Fungal Infections 93

Nov 21, 2014: Basilea Reports That U.S. FDA Sets Date Of Advisory Committee Meeting On Isavuconazole NDA For The Treatment Of Invasive Aspergillosis And Mucormycosis 93

Sep 09, 2014: F2G Announces A Major Funding Award From The Technology Strategy Board`s Biomedical Catalyst 93

Sep 06, 2014: Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis 94

Sep 05, 2014: Astellas to Showcase Isavuconazole Data at ICAAC 94

Appendix 97

Methodology 97

Coverage 97

Secondary Research 97

Primary Research 97

Expert Panel Validation 97

Contact Us 97

Disclaimer 98

List of Tables

Number of Products under Development for Aspergillosis, H1 2015 10

Number of Products under Development for Aspergillosis-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Aspergillosis-Pipeline by Amplyx Pharmaceuticals, Inc., H1 2015 21

Aspergillosis-Pipeline by Astellas Pharma Inc., H1 2015 22

Aspergillosis-Pipeline by Aureogen Biosciences, Inc., H1 2015 23

Aspergillosis-Pipeline by Basilea Pharmaceutica AG, H1 2015 24

Aspergillosis-Pipeline by Biomar Microbial Technologies, H1 2015 25

Aspergillosis-Pipeline by Eisai Co., Ltd., H1 2015 26

Aspergillosis-Pipeline by F2G Ltd, H1 2015 27

Aspergillosis-Pipeline by iCo Therapeutics Inc., H1 2015 28

Aspergillosis-Pipeline by MABLife S.A.S, H1 2015 29

Aspergillosis-Pipeline by Merck & Co., Inc., H1 2015 30

Aspergillosis-Pipeline by Nanomerics Ltd, H1 2015 31

Aspergillosis-Pipeline by Novabiotics Ltd, H1 2015 32

Aspergillosis-Pipeline by Pulmocide Ltd, H1 2015 33

Aspergillosis-Pipeline by Scynexis, Inc., H1 2015 34

Aspergillosis-Pipeline by Sealife PHARMA GMBH, H1 2015 35

Aspergillosis-Pipeline by Sigma-Tau S.p.A., H1 2015 36

Aspergillosis-Pipeline by Vical Incorporated, H1 2015 37

Assessment by Monotherapy Products, H1 2015 38

Number of Products by Stage and Target, H1 2015 40

Number of Products by Stage and Mechanism of Action, H1 2015 42

Number of Products by Stage and Route of Administration, H1 2015 44

Number of Products by Stage and Molecule Type, H1 2015 46

Aspergillosis Therapeutics-Recent Pipeline Updates, H1 2015 79

Aspergillosis-Dormant Projects, H1 2015 87

Aspergillosis-Discontinued Products, H1 2015 88

List of Figures

Number of Products under Development for Aspergillosis, H1 2015 10

Number of Products under Development for Aspergillosis-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 38

Number of Products by Top 10 Targets, H1 2015 39

Number of Products by Stage and Top 10 Targets, H1 2015 40

Number of Products by Top 10 Mechanism of Actions, H1 2015 41

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 42

Number of Products by Top 10 Routes of Administration, H1 2015 43

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 44

Number of Products by Top 10 Molecule Types, H1 2015 45

Number of Products by Stage and Top 10 Molecule Types, H1 2015 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Amplyx Pharmaceuticals, Inc.

Astellas Pharma Inc.

Aureogen Biosciences, Inc.

Basilea Pharmaceutica AG

Biomar Microbial Technologies

Eisai Co., Ltd.

F2G Ltd

iCo Therapeutics Inc.


Merck & Co., Inc.

Nanomerics Ltd

Novabiotics Ltd

Pulmocide Ltd

Scynexis, Inc.


Sigma-Tau S.p.A.

Vical Incorporated

Aspergillosis Therapeutic Products under Development, Key Players in Aspergillosis Therapeutics, Aspergillosis Pipeline Overview, Aspergillosis Pipeline, Aspergillosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 132860
Site License
USD 4000 INR 265720
Corporate User License
USD 6000 INR 398580



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]